Clinical Trials Logo

Colon Cancer clinical trials

View clinical trials related to Colon Cancer.

Filter by:

NCT ID: NCT04369053 Active, not recruiting - Colorectal Cancer Clinical Trials

Prevention of Colorectal Cancer Through Multiomics Blood Testing

PREEMPT CRC
Start date: May 20, 2020
Phase:
Study type: Observational

The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.

NCT ID: NCT04364373 Recruiting - Colon Cancer Clinical Trials

D2 vs D3 Lymph Node Dissection for Left Colon Cancer

DILEMMA
Start date: March 31, 2020
Phase: N/A
Study type: Interventional

The efficiency of the D3 lymph node dissection is still controversial for left colon cancer patients. This study will try find difference in 5-year overall survival between D2 and D3 lymph node dissection. Investigation of the functional and short-term outcomes will clarify safety of the D3 lymph node dissection.

NCT ID: NCT04354246 Recruiting - Lung Cancer Clinical Trials

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Start date: March 31, 2020
Phase: Phase 1
Study type: Interventional

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

NCT ID: NCT04354064 Recruiting - Breast Cancer Clinical Trials

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Start date: May 29, 2019
Phase:
Study type: Observational

Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.

NCT ID: NCT04351009 Completed - Colon Cancer Clinical Trials

Sentinel Lymph Node Mapping and Analysis in Colon Cancer Using Indocyanine Green Dye

Start date: June 8, 2020
Phase: N/A
Study type: Interventional

Approximately 20-30 % of colon cancer patients who have no metastasis in lymph nodes after definitive colectomy have recurrence with distant metastasis. These recurrences could be due to missed occult tumor cells or micrometastasis. Detailed examination of all lymph nodes is expensive and time consuming. Sentinel lymph node mapping using Indocyanine green dye helps in identifying the lymph nodes which are most likely to harbour metastasis. These sentinel lymph nodes can be subsequently subjected to detailed pathologic examination and immunohistochemistry which increases the likelihood of identifying micrometastasis and occult tumor cells. Patients found to harbour such metastasis can be treated with additional chemotherapy after surgery. The aim of the study is to examine the feasibility of sentinel lymph node mapping using Indocyanine green dye in colon cancer and evaluate the upstaging rate in post-operative colon cancer patients who don't have metastatic lymph nodes on routine histopathology.

NCT ID: NCT04348188 Not yet recruiting - Breast Cancer Clinical Trials

Study of the Effectiveness of Supervised vs. Non-Supervised Therapeutic Exercise in Cancer Patients

Start date: June 2020
Phase: N/A
Study type: Interventional

AIM:To evaluate the effectiveness of a therapeutic exercise program (PET) in cancer patients in improving the quality of life and the need for supervision by health professionals during the performance of same after 6 weeks of intervention. DESIGN: Randomized and controlled clinical trial, parallel groups with active control group. With masking of randomization, patient evaluation and analysis of the data. SUBJETS OF STUDY: 58 patients diagnosed with breast and colon cancer and treated up to 2 years later, both with surgery, chemotherapy and hormonal treatments (inhibitors of aromatase, tamoxifen). INTERVENTION: both groups the treatment will be a common work-based therapeutic exercise program aerobic, strength-resistance and self-stretching, in addition to a reinforcement in recommendations usual self-care. The study includes two phases, phase of supervised work and phase of tracing. One of the groups will be supervised in the realization of PET for a period of 6weeks and the other group will do it autonomously and without supervision. The patients will be followed for 1 year, with five blind evaluations: at the beginning of the study, after 6 weeks of intervention, 3, 6 and 12 months after the start of the study.MEASUREMENTS: Principal: Quality of life assessed with the questionnaire measured with the European questionnaire Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-30). Pre-post intervention measure, 3, 6 and 12 months. Secondary: Cancer-related fatigue evaluated with the Functional Assessment of scale Chronic Illness Therapy - Fatigue (FACIT-F). Pre-post Measurement intervention, 3, 6 and 12 months. Functional capacity measured with the Test 6 minutes walking test. Pre-post Measurement intervention, 3, 6 and 12 months. Valuation of the measured force with manual hydraulic dynamometer and 5- test repetition sit-to-stand. Pre-post intervention measure, 3, 6 and 12 months.COST: effectiveness and cost / incremental utility associated to the program wil be estimated.

NCT ID: NCT04316078 Completed - Gastric Cancer Clinical Trials

A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies

Start date: March 15, 2020
Phase: N/A
Study type: Interventional

A randomized control trial to evaluate the feasibility of implementing a patient educational platform (PEP) for patients with gastrointestinal malignancies undergoing active chemotherapy treatment.

NCT ID: NCT04311099 Recruiting - Surgery Clinical Trials

Optimal Peripheral Nerve Block After Minimally Invasive Colon Surgery

OPMICS
Start date: January 14, 2021
Phase: Phase 4
Study type: Interventional

The purpose of the trial is to identify the "most simple non-inferior of three different methods", placebo, laparoscopic assisted transverse abdominal plane block (L-TAP) and ultrasound guided TAP block (US-TAP), using postoperative opioid consumption as a measure of efficacy in patients undergoing elective minimally invasive colon surgery in an ERAS setting. Postoperative pain scores and length of stay (LOS) will also be measured. The simplicity of the three methods is ranked as: 1) placebo, 2) L-TAP and 3) US-TAP.

NCT ID: NCT04270461 Withdrawn - Clinical trials for Hepatocellular Carcinoma

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Start date: March 17, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

NCT ID: NCT04269369 Not yet recruiting - Esophageal Cancer Clinical Trials

Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients

Start date: February 18, 2020
Phase: Phase 4
Study type: Interventional

The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU (5-fluorouracil) or capecitabine. Therefore, a monocentric, partial prospective and partial retrospective trail was designed.